<![CDATA[Lutikizumab Meets Primary End Point in Phase 3 HS Trial]]>

Дата публикации: 22-10-2026 14:13:36

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	<![CDATA[AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines]]>	0	16.9	20-10-2026
2	<![CDATA[Mirikizumab Linked to Higher Rates of Corticosteroid-Free Composite Remission in UC and Crohn Disease]]>	0	14.69	15-10-2026
3	<![CDATA[How Emerging Oral Therapies Target HS Inflammation]]>	0	7.2	20-10-2026
4	<![CDATA[Efficacy and Safety Data for Emerging Oral HS Agents]]>	0	7.35	20-10-2026
5	<![CDATA[Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial]]>	0	9.13	30-09-2026
6	<![CDATA[Cosibelimab-ipdl Gets NCCN Category 2A Nod for Locally Advanced CSCC]]>	0	9.57	22-10-2026
7	Mejoran la respuesta a un tratamiento clave en un tipo agresivo de linfoma	0	8.52	15-04-2026
8	Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)	0	18.81	22-06-2026
9	<![CDATA[Nonsteroidal Topicals Guide Special-Site Psoriasis Treatment Decisions]]>	0	16.35	21-10-2026
10	<![CDATA[Tolerability and Response Criteria Guide Hedgehog Inhibitor Choice in Advanced BCC]]>	0	7.94	22-10-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.47. Источник: www.dermatologytimes.com.